drugset / Trial / NCT00827359
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Phase 2
Completed
25 enrolled
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collabDuke University · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if certain features of tumor specimens sampled prior to therapy can predict for the likelihood of responding to everolimus.
Timeline
- Start
- 2009-03
- Primary completion
- 2018-01
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | Oral |